AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02659501
Drug: Bupivacaine with epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
Trial: NCT01950260
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
Trial: NCT03517033
Drug: Forest Pharmaceuticals Inc.'s Bystolic Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00475397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02659501
Drug: Hydrocodone/acetaminophen
RxNorm normalized name: hydrocodone/acetaminophen 5 mg-500 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
Trial: NCT04496167
Drug: EN3835
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase clostridium histolyticum
Trial: NCT04496167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT02921022
Drug: PEGPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04160520
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Establish proof of concept that low dose morphine in combination with pramipexole is non-inferior to standard dose morphine with respect to providing analgesia in patients presenting to the ED with pain associated with renal colic.
Trial: NCT01071889
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - only excipients with no API
Trial: NCT00816140
Drug: Cravit based triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin based triple therapy~LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days
Trial: NCT00816140
Drug: Klaricid based triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin based triple therapy~CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days
Trial: NCT01537354
Drug: Curosurf®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).
Trial: NCT01537354
Drug: Survanta®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
Trial: NCT01893528
Drug: REGN2009
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03891680
Drug: Botox Injectable Product
RxNorm normalized name: Botox Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra articular Botox injection
Trial: NCT02967211
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT04816994
Drug: Single-dose of cannabis oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of cannabis oil in order to treat acute radicular pain
Trial: NCT01001559
Drug: Serotonin and norepinephrine reuptake inhibitor (SNRI)
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
Trial: NCT02617680
Drug: desflurane - oxygen in nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
Trial: NCT02475629
Drug: Optimized Background Regimen (OBR)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
Trial: NCT01878799
Drug: GS-7977/GS- 5885 FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
Trial: NCT02025348
Drug: IntelliCap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.
Trial: NCT01520220
Drug: LY2784544
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
Trial: NCT02757391
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04320706
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo orally
Trial: NCT00901823
Drug: Diazoxide choline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
Trial: NCT00901823
Drug: Diazoxide choline high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
Trial: NCT03219515
Drug: Gongjin-Dan
RxNorm normalized name: PANAX GINSENG FRUIT 229 mg in 4 g ORAL PELLET [Korea Gongjin-Dan]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.
Trial: NCT03219515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
Trial: NCT02242760
Drug: SB204 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically twice daily
Trial: NCT02242760
Drug: SB204 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically daily
Trial: NCT00386334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet one per day in the evening.
Trial: NCT02337062
Drug: APD421
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02337062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03580005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Match Quillichew ERCT
Trial: NCT02242760
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically twice and once daily
Trial: NCT03341689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: microcrystalline cellulose capsule
Trial: NCT00391131
Drug: IgNextGen 16%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
Trial: NCT01233102
Drug: Conserved Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conserved Therapy
Trial: NCT02781064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin and matching placebo to be taken in a randomised order for 12 months
Trial: NCT01318811
Drug: Dilute unfractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
Trial: NCT01318811
Drug: Standard concentration unfractionated heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
Trial: NCT00398645
Drug: GW685698X 200mcg,GW685698X 200mcg and 400mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02059785
Drug: Pinocembrin for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04002401
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered according to package insert
Trial: NCT03756129
Drug: MIJ821
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different dosages and different regimen for MIJ821
Trial: NCT03756129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion
Trial: NCT02461329
Drug: Gelofusine® B. Braun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
Trial: NCT01978457
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03211065
Drug: 20% subcutaneous immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Immunoglobulin
Trial: NCT02461329
Drug: Ringerfundin ® B. Braun
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets
Trial: NCT02337751
Drug: TVP-1012 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVP-1012 1mg Tablets
Trial: NCT03373201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule
Trial: NCT00218660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02321852
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral administration of placebo mannitol for 7 days
Trial: NCT02442492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
Trial: NCT02947893
Drug: Placebo Capsule(s) Once a Day by Mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
Trial: NCT01107730
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01524601
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg rosuvastatin for 4 weeks
Trial: NCT04159896
Drug: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00813111
Drug: SKY0402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg SKY0402 instilled into breast pocket during surgery
Trial: NCT02238353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01293305
Drug: Chondroitin sulfate + Glucosamine sulfate
RxNorm normalized name: chondroitin sulfates / glucosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 sachet per day of the drug dissolved in a beaker with 200 mL water.
Trial: NCT02735031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 weeks treatment with placebo on top of insulin treatment
Trial: NCT01568853
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenously, 10 ug/min, 24 hours
Trial: NCT04905043
Drug: SmartPill®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participnats will receive a single oral dose of wireless motility/pH capsule (SmartPill®) on Day 1 (Period 1) and Day 4 (Period 2).
Trial: NCT00915590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custom eye drop eye three times a day in both eyes for a period of 6 weeks
Trial: NCT03356860
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV Q 2 weeks from week 14 to week 20
Trial: NCT00681460
Drug: human recombined insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
Trial: NCT01934361
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
Trial: NCT02440009
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
Trial: NCT02962960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous administration every two weeks from week 0 to week 50
Trial: NCT00638781
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00179140
Drug: nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat
Trial: NCT02426697
Drug: fentanyl transmucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
Trial: NCT02426697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
Trial: NCT04395768
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active comparator group will receive: a combination of 2 drugs and 3 dietary supplements
Trial: NCT04159961
Drug: DWJ211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inject the Drug into submental fat and abdominal fat via subcutaneous
Trial: NCT03293641
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
Trial: NCT00494663
Drug: DIO-902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg tablet once per day for 16 weeks
Trial: NCT00494663
Drug: DIO-902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg tablet once per day for 16 weeks
Trial: NCT00494663
Drug: DIO-902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450mg DIO-902 tablet once daily for 16 weeks
Trial: NCT00494663
Drug: DIO-902 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIO-902 placebo tablet once daily for 16 weeks
Trial: NCT00494663
Drug: DIO-902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg tablet of DIO-902 once daily for 16 weeks
Trial: NCT00494663
Drug: DIO-902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg DIO-902 tablet daily for 16 weeks
Trial: NCT00494663
Drug: DIO-902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450mg DIO-902 tablet for 16 weeks
Trial: NCT00578903
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
Trial: NCT04974073
Drug: PHY606
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
Trial: NCT00003012
Drug: CMF regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003012
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003012
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003012
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02858401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet(s) administered orally once every 2 weeks
Trial: NCT02858401
Drug: ARV regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
Trial: NCT00689065
Drug: CALAA-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
Trial: NCT04556760
Drug: AZD9567
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 72 mg/day (oral suspension) of AZD9567 for 3 consecutive days of each treatment period in Cohort 1 and 40 mg/day for 3 consecutive days of each treatment period in Cohort 2.
Trial: NCT04556760
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive 40 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 1, 20 mg/day of prednisolone for 3 consecutive days of each treatment period in Cohort 2, and 5 mg/day prednisolone for 3 consecutive days of each treatment period in Cohort 3.
Trial: NCT04536363
Drug: Analogs, Prostaglandin E1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analog of PGE1:~Infusion starting dose: 0.05 -0.01 mcg per kilogram of weight per minute in infusion continues, maximum 7 days, until achieving the desired clinical response (increase in PaO2), at that time decrease the infusion rate to the lowest dose possible to keep answer. This can be accomplished by decreasing the dose from 0.1 to 0.05 to 0.025 to 0.01 mcg / kg / min.~If the response to 0.05 mcg / kg / min is inadequate, the dose can be increased to 0.4 mcg / kg / min, although in general high doses do not produce better effects. Maximum continuous infusion for up to 7 days
Trial: NCT02202005
Drug: Viramune®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viramune® 400 mg Retardtabletten
Trial: NCT02947269
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT05468892
Drug: Trifluridine Tipiracil
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine-Tipiracil will be administered at 35 mg per square meter orally twice daily, with a glass of water within 1 hour after completion of morning and evening meals, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period. One treatment cycle with Trifluridine-Tipiracil consists of the following:~Days 1-5: Trifluridine / Tipiracil (35 mg/m2/dose) orally twice daily Days 6-7: Rest Days 8-12: Trifluridine / Tipiracil(35mg/m²/dose) orally twice daily Days 13-28: Rest
Trial: NCT00107822
Drug: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
FDA approved: no
EMA approved: no
PMDA approved: no